Healthcare Industry News: Cook
News Release - October 18, 2011
Colibri Heart Valve, LLC Announces Appointment of Joseph B. Horn, President and CEOPrepares for First-in-Human Study of Transcatheter Aortic Heart Valve Implantation (“TAVI”) Device
BROOMFIELD, Colo.--(Healthcare Sales & Marketing Network)-- Colibri Heart Valve, LLC, a privately held medical device company, announced that Joseph B. Horn has joined the company as President and Chief Executive Officer. Colibri Heart Valve has developed the world’s first and only dry, pre-mounted and pre-packaged low profile, 14 French, transcatheter aortic heart valve that advances current TAVI technologies by incorporating advantages not available in any other device, either currently available or in known development.
“Having been in the cardiovascular medical device industry for most of my career, I was impressed by the potential for Colibri’s TAVI device to revolutionize the transcatheter aortic heart valve market,” said Joseph B. Horn. “Given the significant advantages offered by Colibri’s system over existing options, I believe Colibri’s TAVI device has great potential to impact what is predicted to be one of the largest cardiovascular growth markets. We are finalizing plans for our first-in-human study in patients with a symptomatic stenotic aortic valve who are candidates for TAVI, which we expect to complete in identified centers in Western Europe early next year.”
Mr. Horn has spent the last 30+ years in the medical industry, ranging from orthopedics to cardiovascular applications. He is a successful medical device entrepreneur and has focused on cardiology for the last 25 years. Prior to joining Colibri, he last served as a President of a Cook Group company, Global Therapeutics, a company he founded in 1990 where he was responsible for the development and marketing of vascular products in over 40 countries. Global Therapeutics was acquired by Cook in 1998.
About the Colibri TAVI Device
TAVI is likely to become an important treatment option in the US for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience as an approved procedure in Europe, and reduced procedural costs. Colibri’s heart valve device advances current TAVI technologies by incorporating advantages not available in any other device, either currently available or in known development. These advantages are realized through unique features including a significant profile reduction compared to other currently available devices, a folded valve construct using minimal sutures, thin and durable low-profile tissue leaflets, a dry valve which is pre-mounted at manufacture and pre-packaged with the valve fully integrated on its delivery system. The proprietary double balloon technology allows stabilized valve deployment and adjustment capabilities for accurate valve placement. Colibri’s proprietary tissue preparation process makes the Colibri TAVI device highly biocompatible and resistant to calcification.
About Colibri Heart Valve, LLC
Colibri Heart Valve, LLC is a privately held medical device company committed to the research and development of novel heart valve technologies, including the Company’s dry, pre-mounted, low profile, “package-to-patient” percutaneous Transcatheter Heart Valve (THV). The unique features of this system include its delivery technology and durable valve tissue, potentially providing major benefit by decreasing procedural vascular complications and improving overall TAVI outcomes. Colibri Heart Valve was founded by R. David Fish, MD, and David Paniagua, MD, pioneering interventional cardiologists. Colibri’s corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. For more information, visit: www.colibrihv.com.
Source: Colibri Heart Valve
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.